The earnings call highlighted strong revenue growth and successful product performances, particularly for Cortrophin Gel, along with raised financial guidance. However, it also acknowledged market access challenges in the retina segment and an ongoing legal dispute.

Company Guidance

In the recent earnings call, ANI Pharmaceuticals reported significant growth and revised its 2025 guidance upward across several key metrics. The company now anticipates total net revenues in the range of $818 million to $843 million, marking a 33% to 37% increase over 2024, up from the prior guidance of $768 million to $793 million. Adjusted non-GAAP EBITDA is expected to be between $213 million and $223 million, reflecting a growth of 37% to 43% over the previous year, compared to earlier projections of $195 million to $205 million. Additionally, adjusted non-GAAP EPS is revised to $6.98 to $7.35, up from the prior range of $6.27 to $6.62. This robust performance is largely driven by the Rare Disease business, particularly the Cortrophin Gel, which is now projected to generate revenues between $322 million and $329 million, up from $265 million to $274 million, representing a year-over-year growth of 63% to 66%.

Record-Setting Quarter

ANI Pharmaceuticals achieved record highs in net revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP EPS, reflecting strong momentum across Rare Disease and Generics business units.

Cortrophin Gel Performance

Cortrophin Gel revenues reached $81.6 million, up 66% year-over-year and 54% from the first quarter of 2025, driven by increased demand and new patient starts.

Raised 2025 Guidance

The company raised its 2025 guidance for total net revenues to $818 million to $843 million, representing growth of 33% to 37% over 2024.

Generics Business Performance

Generics business revenues increased by 22% to $90.3 million, driven by new product launches and strong operational execution.

ANI Pharmaceuticals (ANIP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ANIP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	1.67 / -	1.34	―	―	―
Aug 08, 2025	2025 (Q2)	1.41 / 1.80	1.02	76.47% (+0.78)	―
May 09, 2025	2025 (Q1)	1.38 / 1.70	1.21	40.50% (+0.49)	―
Feb 28, 2025	2024 (Q4)	1.44 / 1.63	1	63.00% (+0.63)	―
Nov 08, 2024	2024 (Q3)	1.09 / 1.34	1.27	5.51% (+0.07)	―
Aug 06, 2024	2024 (Q2)	0.95 / 1.02	1.28	-20.31% (-0.26)	―
May 10, 2024	2024 (Q1)	1.00 / 1.21	1.17	3.42% (+0.04)	―
Feb 29, 2024	2023 (Q4)	0.85 / 1.00	0.76	31.58% (+0.24)	―
Nov 08, 2023	2023 (Q3)	0.84 / 1.27	0.64	98.44% (+0.63)	―
Aug 09, 2023	2023 (Q2)	0.67 / 1.28	0.13	884.62% (+1.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ANIP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 08, 2025	$69.01	$81.48	+18.07%
May 09, 2025	$71.53	$66.30	-7.31%
Feb 28, 2025	$54.58	$61.89	+13.39%
Nov 08, 2024	$58.38	$61.44	+5.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ANI Pharmaceuticals Inc (ANIP) report earnings?

ANI Pharmaceuticals Inc (ANIP) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is ANI Pharmaceuticals Inc (ANIP) earnings time?

ANI Pharmaceuticals Inc (ANIP) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ANIP EPS forecast?

ANIP EPS forecast for the fiscal quarter 2025 (Q3) is 1.67.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing